Use of a combination of udenafil and alfuzosin or oxybutynin for the treatment of overactive bladder.

Details for Australian Patent Application No. 2009232027 (hide)

Owner PELVIPHARM

Inventors Behr-Roussel, Delphine; Giuliano, Francois

Agent Griffith Hack

Pub. Number AU-A-2009232027

PCT Pub. Number WO2009/121929

Priority 08300170.1 02.04.08 EP; 61/041 671 02.04.08 US

Filing date 2 April 2009

Wipo publication date 8 October 2009

International Classifications

A61K 31/216 (2006.01)

A61K 31/517 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 31/519 (2006.01) - ortho- or peri-condensed with heterocyclic rings

A61P 13/10 (2006.01) Drugs for disorders of the urinary system

Event Publications

11 November 2010 PCT application entered the National Phase

  PCT publication WO2009/121929 Priority application(s): WO2009/121929

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009232033-Pharmaceutical composition with bisphosphonate

2009232017-1-heterocyclyl-1,5-dihydro-pyrazolo[3,4d] pyrimidin-4-one derivatives and their use as PDE9A modulators